PAIN - Postoperative Analgesia INvestigation

Postoperative Pain Clinical Trial

— PAIN  

Official title:

A Prospective Randomized-controlled Study on Effectiveness of Extended-release Liposomal Bupivacaine in Postoperative Pain Control

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02111746
• Other study ID #: CTVS-KC02
• Secondary ID: HSC-MS-13-0620
• Status: Completed
• Phase: Phase 4
• Start date: November 20, 2013
• Est. completion date: June 30, 2017

Study information

• Verified date: September 2018
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of the intraoperative injection of prolonged acting (liposomal) bupivacaine in postoperative pain control after truncal surgical incisions.

Description:

Study Design:

This is a prospective, single-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing bupivacaine liposomal injectable suspension (Exparel®) versus regular bupivacaine hydrochloride (HCl).

Procedure:

In patients aged 18 and over who require sternotomy, thoracotomy, mini-thoracotomy, or laparotomy incisions will be screened and consented for potential enrollment. Patients will be randomized following consenting to either Exparel® or regular bupivacaine hydrochloride group.

Course of Study:

The study will accrue patients over the course of 4 years.

Enrollment:

Enrollment will consist of all adult patients aged 18 and over undergoing surgical procedures requiring sternotomy, thoracotomy, mini-thoracotomy, or laparotomy incisions. Patients will be screened and consented preoperatively. If the patient is deemed eligible and consents to participate, randomization will occur and the patient will be considered enrolled.

Recruitment:

The target for enrollment will be 280 patients (the study target sample size per power analysis, but actual enrollment will be greater (330 patients) to account for exclusions for various reasons in order to achieve the target recruitment).

Risks:

There is a small increased risk to the patients by participating in the study in addition to a possible chance of breach in patient confidentiality as the study involves evaluation of an FDA-approved drug. As detailed in the informed consent, the subjects are at risk of developing adverse effects from Exparel®, described on the drug packet insert and from HCl Bupivacaine, also described on the drug packet insert. The investigators do not expect any additional physical risks other than an unintentional disclosure of sensitive patient health information.

Data Safety Monitoring:

As the Principal Investigator of this study, Dr. Charlton-Ouw from the Department of Cardiothoracic and Vascular Surgery at The University of Texas at Houston Medical School will conduct the data safety monitoring of this study. He will annually meet with all other co-investigators to review the patients enrolled in this study. As part of the data safety monitoring plan, all patients enrolled until that point in time would be unblinded in order to review the outcomes. Additionally, in view of the uncertainty attached to the treatment effects in this heterogeneous population, owing to limited currently available data, an independent Data Safety Monitoring Committee, will oversee the progress of the trial.

IND#:

The drugs that will be used are already approved by the FDA and do not have IND/IDE#

Proposed Funding Source:

The study is internally funded and is investigator-initiated.

Communication of Study Results:

The communication of study results will occur only between authorized individuals who are listed to take part in the study through our department. The individuals who will take part in the study will acknowledge and adhere to the importance of patient safety and the protection of their private information. The results of this study will be analyzed and published after the approval of the principal investigator, co-investigators, and biostatistician in a peer-reviewed scientific journal and/or presented at an international/national scientific conference or meeting regardless of outcome.

Other known NCT identifiers

• NCT02474472

Recruitment information / eligibility

• Status: Completed
• Enrollment: 350
• Est. completion date: June 30, 2017
• Est. primary completion date: May 3, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years-old or older, and

• Sternotomy, thoracotomy, laparotomy or mini-thoracotomy incision is planned

• There is reasonable expectation that the patient will be extubated within 24 hours after surgery

Exclusion Criteria:

• The patient has a known allergy to morphine or any opioid

• The patient has a known chronic pain disorder or takes daily opioid medication > 1 month prior to surgery

• There is anticipated difficulty communicating pain status due to language or other barriers at the investigator discretion

• High postoperative morbidity index based on preoperative assessment, such as, low likelihood of extubation within 24 hours, extensive thoracoabdominal aortic aneurysm (Extent 2 TAAA), preoperative renal insufficiency/failure, etc.

Related Conditions & MeSH terms

• Pain, Postoperative
• Postoperative Pain

Intervention

Drug:
• Exparel
Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
• Bupivacaine hydrochloride
Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
• Patient Controlled Analgesia (PCA)
Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day

Locations

Country	Name	City	State
United States	Department of Cardiothoracic and Vascular Surgery and Memorial Hermann Heart and Vascular Institute - Texas Medical Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative Pain as Assessed by a Numeric Pain Scale (NPS)	The Numeric Pain Scale (NPS) ranges from 0 ("no pain") to 10 ("worst possible pain").	postoperative day 1
Primary	Postoperative Pain as Assessed by a Numeric Pain Scale (NPS)	The Numeric Pain Scale (NPS) ranges from 0 ("no pain") to 10 ("worst possible pain").	postoperative day 2
Primary	Postoperative Pain as Assessed by a Numeric Pain Scale (NPS)	The Numeric Pain Scale (NPS) ranges from 0 ("no pain") to 10 ("worst possible pain").	postoperative day 3
Primary	Postoperative Pain as Assessed by a Five-point Satisfaction Scale	The 5-point satisfaction scale ranges from 1 (extremely dissatisfied) to 5 (extremely satisfied).	postoperative day 1
Primary	Postoperative Pain as Assessed by a Five-point Satisfaction Scale	The 5-point satisfaction scale ranges from 1 (extremely dissatisfied) to 5 (extremely satisfied).	postoperative day 2
Primary	Postoperative Pain as Assessed by a Five-point Satisfaction Scale	The 5-point satisfaction scale ranges from 1 (extremely dissatisfied) to 5 (extremely satisfied).	postoperative day 3
Primary	Postoperative Pain as Assessed by the Brief Pain Inventory (BPI)	The Brief Pain Inventory (BPI) ranges from 0 ("no pain") to 10 ("worst pain you can imagine").	postoperative day 1
Primary	Postoperative Pain as Assessed by the Brief Pain Inventory (BPI)	The Brief Pain Inventory (BPI) ranges from 0 ("no pain") to 10 ("worst pain you can imagine").	postoperative day 2
Primary	Postoperative Pain as Assessed by the Brief Pain Inventory (BPI)	The Brief Pain Inventory (BPI) ranges from 0 ("no pain") to 10 ("worst pain you can imagine").	postoperative day 3
Secondary	Overall Opioid Use	The total amount in mg of opioid medication consumed through 12, 24, 36, 48, 60, and 72 hours after surgery will be assessed.	Over the first 72 hours after surgery
Secondary	Mean Length of Hospital Stay	Indirect outcome measure to assess the adequacy of postoperative pain control as an indicator of improvement in healing period, patient participation in physical therapy and faster patient mobilization, and overall health care cost	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Change From Baseline in Quality of Life	The impact of pain on patient's quality of life will be assessed through a brief pain inventory (BPI). In addition, the 5-point scale analgesia satisfaction survey will be used along with the BPI to assess patient satisfaction and quality of life.	Will be assessed preoperatively, on the first post-op day (POD 1), on POD2, and POD 3
Secondary	Number of Participants Who Attain Physical Therapy Goal That Justifies Discharge From Inpatient Physical Therapy Within 72 Hours		72 hours after surgery
Secondary	Hospital Cost for Patient Care During Hospitalization	Hospital cost for patient care during hospitalization will be estimated from hospital charges and financial records.	duration of hospital stay, an expected average of 4 weeks